Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

RMD open

Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Klami Kristianslund E, Kvien TK, Provan SA, Björn Guðbjörnsson B, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson L, Askling J.
PMID: 29682328
RMD Open. 2018 Apr 12;4(1):e000655. doi: 10.1136/rmdopen-2018-000655. eCollection 2018.

There are increasing needs for detailed real-world data on rheumatic diseases and their treatments. Clinical register data are essential sources of information that can be enriched through linkage to additional data sources such as national health data registers. Detailed...

Cite
Chatzidionysiou K, Hetland ML, Frisell T, et al. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open. 2018;4(1):e000655doi: 10.1136/rmdopen-2018-000655.
Chatzidionysiou, K., Hetland, M. L., Frisell, T., Di Giuseppe, D., Hellgren, K., Glintborg, B., Nordström, D., Aaltonen, K., Törmänen, M. R., Klami Kristianslund, E., Kvien, T. K., Provan, S. A., Björn Guðbjörnsson, B., Dreyer, L., Kristensen, L. E., Jørgensen, T. S., Jacobsson, L., & Askling, J. (2018). Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD open, 4(1), e000655. https://doi.org/10.1136/rmdopen-2018-000655
Chatzidionysiou, Katerina, et al. "Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example." RMD open vol. 4,1 (2018): e000655. doi: https://doi.org/10.1136/rmdopen-2018-000655
Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Klami Kristianslund E, Kvien TK, Provan SA, Björn Guðbjörnsson B, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson L, Askling J. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open. 2018 Apr 12;4(1):e000655. doi: 10.1136/rmdopen-2018-000655. eCollection 2018. PMID: 29682328; PMCID: PMC5905834.
Copy Download .nbib Format: NLM
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision.

RMD open

Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J.
PMID: 34880127
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987.

OBJECTIVES: To compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on rheumatology care provision.METHODS: Through nationwide...

Cite
Bower H, Frisell T, di Giuseppe D, et al. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001987.
Bower, H., Frisell, T., di Giuseppe, D., Delcoigne, B., Ahlenius, G. M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad-d'Elia, H., Kastbom, A., Klareskog, L., Lindqvist, E., Lindström, U., Turesson, C., Sjowall, C., Askling, J. (2021). Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001987
Bower, Hannah, et al. "Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001987
Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987. PMID: 34880127; PMCID: PMC8655349.
Copy Download .nbib Format: NLM
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.

Rheumatology (Oxford, England)

Di Giuseppe D, Lindstrom U, Bower H, Delcoigne B, Frisell T, Chatzidionysiou K, Sjöwall C, Lindqvist E, Askling J.
PMID: 34919663
Rheumatology (Oxford). 2021 Dec 17; doi: 10.1093/rheumatology/keab933. Epub 2021 Dec 17.

OBJECTIVES: To compare treatment retention between biosimilars and their originator products among first starters (etanercept, infliximab, adalimumab and rituximab), as well as after non-medical switch.METHODS: Patients with rheumatic diseases starting, for the first time, an originator or biosimilar etanercept,...

Cite
Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab933.
Di Giuseppe, D., Lindstrom, U., Bower, H., Delcoigne, B., Frisell, T., Chatzidionysiou, K., Sjöwall, C., Lindqvist, E., Askling, J. (2021). Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab933
Di Giuseppe, Daniela, et al. "Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab933
Di Giuseppe D, Lindstrom U, Bower H, Delcoigne B, Frisell T, Chatzidionysiou K, Sjöwall C, Lindqvist E, Askling J. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2021 Dec 17; doi: 10.1093/rheumatology/keab933. Epub 2021 Dec 17. PMID: 34919663.
Copy Download .nbib Format: NLM
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.

JAMA network open

McKay KA, Piehl F, Englund S, He A, Langer-Gould A, Hillert J, Frisell T.
PMID: 34851401
JAMA Netw Open. 2021 Dec 01;4(12):e2136697. doi: 10.1001/jamanetworkopen.2021.36697.

No abstract available.

Cite
McKay KA, Piehl F, Englund S, et al. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021;4(12):e2136697doi: 10.1001/jamanetworkopen.2021.36697.
McKay, K. A., Piehl, F., Englund, S., He, A., Langer-Gould, A., Hillert, J., & Frisell, T. (2021). Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA network open, 4(12), e2136697. https://doi.org/10.1001/jamanetworkopen.2021.36697
McKay, Kyla A, et al. "Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden." JAMA network open vol. 4,12 (2021): e2136697. doi: https://doi.org/10.1001/jamanetworkopen.2021.36697
McKay KA, Piehl F, Englund S, He A, Langer-Gould A, Hillert J, Frisell T. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 Dec 01;4(12):e2136697. doi: 10.1001/jamanetworkopen.2021.36697. PMID: 34851401; PMCID: PMC8637249.
Copy Download .nbib Format: NLM
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology.

RMD open

Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Landewé RB, Finckh A, Bergstra SA, Courvoisier DS.
PMID: 34789534
RMD Open. 2021 Nov;7(3). doi: 10.1136/rmdopen-2021-001818.

OBJECTIVES: To evaluate the analysis and reporting of comparative effectiveness research with observational data in rheumatology, informing European Alliance of Associations for Rheumatology points to consider.METHODS: We performed a systematic literature review searching Ovid MEDLINE for original articles comparing...

Cite
Lauper K, Kedra J, de Wit M, et al. Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001818.
Lauper, K., Kedra, J., de Wit, M., Fautrel, B., Frisell, T., Hyrich, K. L., Iannone, F., Machado, P. M., Ørnbjerg, L. M., Rotar, Z., Santos, M. J., Stamm, T. A., Stones, S. R., Strangfeld, A., Landewé, R. B., Finckh, A., Bergstra, S. A., & Courvoisier, D. S. (2021). Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001818
Lauper, Kim, et al. "Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001818
Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Landewé RB, Finckh A, Bergstra SA, Courvoisier DS. Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open. 2021 Nov;7(3). doi: 10.1136/rmdopen-2021-001818. PMID: 34789534; PMCID: PMC8601074.
Copy Download .nbib Format: NLM
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision.

RMD open

Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J.
PMID: 34880127
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987.

OBJECTIVES: To compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on rheumatology care provision.METHODS: Through nationwide...

Cite
Bower H, Frisell T, di Giuseppe D, et al. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001987.
Bower, H., Frisell, T., di Giuseppe, D., Delcoigne, B., Ahlenius, G. M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad-d'Elia, H., Kastbom, A., Klareskog, L., Lindqvist, E., Lindström, U., Turesson, C., Sjowall, C., Askling, J. (2021). Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001987
Bower, Hannah, et al. "Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001987
Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987. PMID: 34880127; PMCID: PMC8655349.
Copy Download .nbib Format: NLM
What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?.

ACR open rheumatology

Westerlind H, Maciejewski M, Frisell T, Jelinsky SA, Ziemek D, Askling J.
PMID: 34085401
ACR Open Rheumatol. 2021 Jul;3(7):457-463. doi: 10.1002/acr2.11266. Epub 2021 Jun 04.

OBJECTIVE: The objectives of this study were to assess the 1-year persistence to methotrexate (MTX) initiated as the first ever conventional synthetic disease-modifying antirheumatic drug in new-onset rheumatoid arthritis (RA) and to investigate the marginal gains and robustness of...

Cite
Westerlind H, Maciejewski M, Frisell T, et al. What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?. ACR Open Rheumatol. 2021;3(7):457-463doi: 10.1002/acr2.11266.
Westerlind, H., Maciejewski, M., Frisell, T., Jelinsky, S. A., Ziemek, D., & Askling, J. (2021). What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?. ACR open rheumatology, 3(7), 457-463. https://doi.org/10.1002/acr2.11266
Westerlind, Helga, et al. "What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?." ACR open rheumatology vol. 3,7 (2021): 457-463. doi: https://doi.org/10.1002/acr2.11266
Westerlind H, Maciejewski M, Frisell T, Jelinsky SA, Ziemek D, Askling J. What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?. ACR Open Rheumatol. 2021 Jul;3(7):457-463. doi: 10.1002/acr2.11266. Epub 2021 Jun 04. PMID: 34085401; PMCID: PMC8280803.
Copy Download .nbib Format: NLM
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology.

RMD open

Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Landewé RB, Finckh A, Bergstra SA, Courvoisier DS.
PMID: 34789534
RMD Open. 2021 Nov;7(3). doi: 10.1136/rmdopen-2021-001818.

OBJECTIVES: To evaluate the analysis and reporting of comparative effectiveness research with observational data in rheumatology, informing European Alliance of Associations for Rheumatology points to consider.METHODS: We performed a systematic literature review searching Ovid MEDLINE for original articles comparing...

Cite
Lauper K, Kedra J, de Wit M, et al. Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001818.
Lauper, K., Kedra, J., de Wit, M., Fautrel, B., Frisell, T., Hyrich, K. L., Iannone, F., Machado, P. M., Ørnbjerg, L. M., Rotar, Z., Santos, M. J., Stamm, T. A., Stones, S. R., Strangfeld, A., Landewé, R. B., Finckh, A., Bergstra, S. A., & Courvoisier, D. S. (2021). Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001818
Lauper, Kim, et al. "Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001818
Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Landewé RB, Finckh A, Bergstra SA, Courvoisier DS. Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open. 2021 Nov;7(3). doi: 10.1136/rmdopen-2021-001818. PMID: 34789534; PMCID: PMC8601074.
Copy Download .nbib Format: NLM
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study.

Annals of the rheumatic diseases

Mongin D, Lauper K, Finckh A, Frisell T, Courvoisier DS.
PMID: 35027398
Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221477. Epub 2022 Jan 13.

OBJECTIVES: To assess the performance of statistical methods used to compare the effectiveness between drugs in an observational setting in the presence of attrition.METHODS: In this simulation study, we compared the estimations of low disease activity (LDA) at 1...

Cite
Mongin D, Lauper K, Finckh A, et al. Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Ann Rheum Dis. 2022;doi: 10.1136/annrheumdis-2021-221477.
Mongin, D., Lauper, K., Finckh, A., Frisell, T., & Courvoisier, D. S. (2022). Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221477
Mongin, Denis, et al. "Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study." Annals of the rheumatic diseases vol. (2022). doi: https://doi.org/10.1136/annrheumdis-2021-221477
Mongin D, Lauper K, Finckh A, Frisell T, Courvoisier DS. Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221477. Epub 2022 Jan 13. PMID: 35027398.
Copy Download .nbib Format: NLM
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?.

Annals of the rheumatic diseases

Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Askling J.
PMID: 34810197
Ann Rheum Dis. 2021 Nov 22; doi: 10.1136/annrheumdis-2021-221461. Epub 2021 Nov 22.

OBJECTIVES: To estimate absolute and relative risks for seasonal influenza outcomes in patients with inflammatory joint diseases (IJDs) and disease-modifying antirheumatic drugs (DMARDs). To contextualise recent findings on corresponding COVID-19 risks.METHODS: Using Swedish nationwide registers for this cohort study,...

Cite
Bower H, Frisell T, Di Giuseppe D, et al. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221461.
Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B., & Askling, J. (2021). Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221461
Bower, Hannah, et al. "Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221461
Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Askling J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Ann Rheum Dis. 2021 Nov 22; doi: 10.1136/annrheumdis-2021-221461. Epub 2021 Nov 22. PMID: 34810197; PMCID: PMC8610614.
Copy Download .nbib Format: NLM
Risk of depression in multiple sclerosis across disease-modifying therapies.

Multiple sclerosis (Houndmills, Basingstoke, England)

Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F.
PMID: 34264143
Mult Scler. 2021 Jul 15;13524585211031128. doi: 10.1177/13524585211031128. Epub 2021 Jul 15.

BACKGROUND: Depression and use of antidepressants are more common among patients with multiple sclerosis (MS) compared to the general population, but the relation of psychiatric comorbidity to use of different disease-modifying therapies (DMTs) is less clear.OBJECTIVE: To determine whether...

Cite
Longinetti E, Frisell T, Englund S, et al. Risk of depression in multiple sclerosis across disease-modifying therapies. Mult Scler. 2021;13524585211031128doi: 10.1177/13524585211031128.
Longinetti, E., Frisell, T., Englund, S., Reutfors, J., Fang, F., & Piehl, F. (2021). Risk of depression in multiple sclerosis across disease-modifying therapies. Multiple sclerosis (Houndmills, Basingstoke, England), 13524585211031128. https://doi.org/10.1177/13524585211031128
Longinetti, Elisa, et al. "Risk of depression in multiple sclerosis across disease-modifying therapies." Multiple sclerosis (Houndmills, Basingstoke, England) vol. (2021): 13524585211031128. doi: https://doi.org/10.1177/13524585211031128
Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F. Risk of depression in multiple sclerosis across disease-modifying therapies. Mult Scler. 2021 Jul 15;13524585211031128. doi: 10.1177/13524585211031128. Epub 2021 Jul 15. PMID: 34264143.
Copy Download .nbib Format: NLM
Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.

Rheumatology (Oxford, England)

Huss V, Bower H, Wadström H, Frisell T, Askling J.
PMID: 34324640
Rheumatology (Oxford). 2021 Jul 29; doi: 10.1093/rheumatology/keab570. Epub 2021 Jul 29.

OBJECTIVE: To estimate the occurrence and relative risks of first ever incident non-cutaneous cancer overall and by 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment start, attained age, and...

Cite
Huss V, Bower H, Wadström H, et al. Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab570.
Huss, V., Bower, H., Wadström, H., Frisell, T., Askling, J. (2021). Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab570
Huss, Viking, et al. "Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab570
Huss V, Bower H, Wadström H, Frisell T, Askling J. Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021 Jul 29; doi: 10.1093/rheumatology/keab570. Epub 2021 Jul 29. PMID: 34324640.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries